Mathieu Simon

Mathieu Simon currently works at Idorsia Ltd., as Vice Chairman from 2024, Aileens Pharma Srl, as Chairman, Idorsia Pharmaceuticals Ltd., as Chairman from 2020, Epsilen Bio Srl, as Chairman from 2020, Messier Maris & Associés SCA, as Director, and Affimed GmbH, as Member-Supervisory Board from 2018.
Dr. Simon also formerly worked at Takara Bio Europe AB, as Chairman & Chief Executive Officer from 2012 to 2014, Ectycell SASU, as Chief Executive Officer from 2012 to 2014, Cellectis Therapeutics, as Chief Executive Officer from 2012 to 2014, Asarina Pharma AB, as Independent Director, Alliance for Regenerative Medicine, as Director, YSOPIA Biosciences SA, as Independent Director, Lysogene SA, as Independent Non-Executive Director, Farmindustria, as Director, Wyeth Pharmaceuticals LLC, as Vice President-Marketing & Medical Affairs, Pierre Fabre SA, as Senior VP & Head-Global Pharmaceutical from 2010 to 2011, Pierre Fabre Médicament SAS, as Senior Vice President-Global Operations, Cellectis SA, as EVP, Chief Operating & Medical Officer from 2017 to 2018, Vaximm AG, as Member-Supervisory Board, Wyeth-Ayerst International LLC, as Group VP-Marketing & Clinical Affairs from 1994 to 1997, Affimed NV, as Member-Supervisory Board from 2018 to 2024, and Pierre Fabre SA, as Head-Global Pharma Operations from 2010 to 2011.
Dr. Simon received his undergraduate degree from Université Paris Diderot-Paris 7.